China Pharma Holdings (CPHI) Non-Current Deferred Tax Liability (2010 - 2026)

China Pharma Holdings has reported Non-Current Deferred Tax Liability for 17 years, with the latest figure at $759628.0 in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Deferred Tax Liability rose 3.74% year-over-year to $759628.0; the trailing twelve-month figure through Mar 2026 stood at $759628.0 (up 3.74% YoY), and the FY2025 full-year result was $747805.0, up 2.27% from the prior year.
• Non-Current Deferred Tax Liability for Q1 2026 stood at $759628.0, up from $747805.0 in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $827978.0 in Q1 2022, with the low at $727417.0 in Q2 2023.
• Historically, Non-Current Deferred Tax Liability has averaged $749763.4 across 5 years, with a median of $740828.0 in 2024.
• Annual changes were most pronounced in 2022 — Non-Current Deferred Tax Liability fell 8.65% — and 2026, when it gained 3.74%.
• China Pharma Holdings' Non-Current Deferred Tax Liability stood at $754698.0 in 2022, then decreased by 1.67% to $742114.0 in 2023, then fell by 1.47% to $731202.0 in 2024, then grew by 2.27% to $747805.0 in 2025, then gained by 1.58% to $759628.0 in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $759628.0 (Q1 2026), $747805.0 (Q4 2025), and $739733.0 (Q3 2025), per Business Quant data.